Caesarean section — not reported · women in labour
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Use of pharmacological pain relief ‐ not reported · women in labour
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Length of labour (hours) · women in labour
1 finding from 1 review
Overall survival · Adult patients with myelodysplastic syndromes and thrombocytopenia
1 finding from 1 review
Mortality during study · Adult patients with myelodysplastic syndromes and thrombocytopenia
Thrombopoietin mimetics showed no clear difference in mortality during study compared with placebo (low certainty).
1 finding from 1 review
Transformation to AML · Adult patients with myelodysplastic syndromes and thrombocytopenia
It is very uncertain whether thrombopoietin mimetics changes transformation to AML compared with placebo (very low certainty).
1 finding from 1 review
Incidence of bleeding events · Adult patients with myelodysplastic syndromes and thrombocytopenia
Thrombopoietin mimetics probably leads to lower incidence of bleeding events compared with placebo (moderate certainty).
1 finding from 1 review
Blood transfusion requirements · Adult patients with myelodysplastic syndromes and thrombocytopenia
Thrombopoietin mimetics showed no clear difference in transfusion requirement compared with placebo (low certainty).
1 finding from 1 review
Health‐related quality of life · Adult patients with myelodysplastic syndromes and thrombocytopenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All adverse events · Adult patients with myelodysplastic syndromes and thrombocytopenia
Thrombopoietin mimetics showed no clear difference in all adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · Adult patients with myelodysplastic syndromes and thrombocytopenia
It is very uncertain whether thrombopoietin mimetics changes serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
Failed apnea reduction · treatment of apnea
Doxapram showed no clear difference in 1a. Failed apnea reduction after 2–7 days – doxapram compared to no… compared with no treatment, placebo, methylxanthine (including theophylline,… (low certainty).
3 findings from 1 review
RR 0.45 [0.2, 1.05]
1 study · 21 participants
Low
RR 1.35 [0.53, 3.45]
4 studies · 84 participants
Very low
RR 0.08 [0.01, 1.17]
1 study · 10 participants
Very low
4b. Death at any time during initial hospitalization – doxapram compared to alternative treatment for the treatment of apnea · treatment of apnea
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
5c. Moderate‐to‐severe neurodevelopmental disability or intellectual impairment after 2 years of age – doxapram as an adjunct to methylxanthine compared to methylxanthine alone for the treatment of apnea · treatment of apnea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
side‐effects ‐ side‐effects causing abandon · treatment of apnea
3 findings from 1 review
1c.'Clinical apnea' after initiation of treatment – doxapram as an adjunct to methylxanthine compared to methylxanthine alone for the prevention of reintubation · prevention of reintubation
Doxapram may leads to lower 1c.'Clinical apnea' after initiation of treatment – doxapram as an… compared with no treatment, placebo, methylxanthine (including theophylline,… (low certainty).
1 finding from 1 review
2c. Failed apnea reduction after 2–7 days – doxapram as an adjunct to methylxanthine compared to methylxanthine alone for the prevention of reintubation · prevention of reintubation
Doxapram showed no clear difference in 2c. Failed apnea reduction after 2–7 days – doxapram as an adjunct… compared with no treatment, placebo, methylxanthine (including theophylline,… (low certainty).
1 finding from 1 review
Bronchopulmonary dysplasia/chronic lung disease · prevention of reintubation
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
4a.Death at any time during initial hospitalization – doxapram compared to no treatment for the treatment of apnea · prevention of reintubation
It is very uncertain whether doxapram changes 4c. Death (at any time during initial hospitalization) – doxapram as… compared with no treatment, placebo, methylxanthine (including theophylline,… (very low certainty).
1 finding from 1 review
5c. Moderate‐to‐severe neurodevelopmental disability or intellectual impairment after 2 years of age – doxapram as an adjunct to methylxanthine compared to methylxanthine alone for the prevention of reintubation · prevention of reintubation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found